92664-05-6

Basic information

• Product Name: PotassiuM 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide
• Synonyms: PotassiuM 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide;Ethyl3-cyano-2-oxopropanoatepotassiuMsalt;Propanoic acid, 3-cyano-2-oxo-, ethyl ester, ion(1-), potassium
• CAS NO: 92664-05-6
• Molecular Formula: C₆H₆NO₃*K
• Molecular Weight: 179.21504
• Mol File: 92664-05-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: PotassiuM 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide(CAS DataBase Reference)
• NIST Chemistry Reference: PotassiuM 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide(92664-05-6)
• EPA Substance Registry System: PotassiuM 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide(92664-05-6)

Safety Data

• Hazardous Substances Data: 92664-05-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Potassium 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide serves as a reagent in organic synthesis, facilitating the formation of complex organic molecules. Its unique structure allows it to participate in a variety of chemical reactions, making it a valuable component in the synthesis of new compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, potassium cyanoxalate is utilized in the production of various drugs. Its role in these processes is crucial for the synthesis of active pharmaceutical ingredients, contributing to the development of new medications.
Used in Agrochemical Production:
Similarly, in the agrochemical sector, potassium 1-cyano-3-ethoxy-2,3-dioxopropan-1-ide is employed in the manufacturing of crop protection agents and other agricultural products. Its application in this field aids in the creation of effective solutions to enhance crop yields and protect against pests and diseases.

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 75-05-8 acetonitrile 

Downstream Products

• 1032334-56-7 5-amino-1H-pyrazole-3-carboxylic acid hydrochloride 
• 728896-69-3 N-methoxycarbonyl-3-aminopyrazole-5-carboxylic acid ethyl ester 
• 866837-96-9 5-amino-3-ethoxycarbonyl-1-phenylpyraole 

Relevant articles and documents

New geldanamycin derivatives with anti Hsp properties by mutasynthesis

Mutasynthetic supplementation of the AHBA blocked mutant strain of S. hygroscopicus, the geldanamycin producer, with 21 aromatic and heteroaromatic amino acids provided new nonquinoid geldanamycin derivatives. Large scale (5 L) fermentation provided four new derivatives in sufficient quantity for full structural characterisation. Among these, the first thiophene derivative of reblastatin showed strong antiproliferative activity towards several human cancer cell lines. Additionally, inhibitory effects on human heat shock protein Hsp90α and bacterial heat shock protein from H. pylori HpHtpG were observed, revealing strong displacement properties for labelled ATP and demonstrating that the ATP-binding site of Hsps is the target site for the new geldanamycin derivatives.

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors

Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23.

HETEROCYCLIC INHIBITORS OF MCT4

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES

Compounds are provided that act as potent antagonists of the CCR(9) receptor for treating Sjogren's syndrome. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions.

Design, synthesis and biological evaluation of new pyrazolyl-ureas and imidazopyrazolecarboxamides able to interfere with MAPK and PI3K upstream signaling involved in the angiogenesis

Taking into account the structure activity relationship information given by our previous studies, we designed and synthesized a small library of pyrazolylureas and imidazopyrazolecarboxamides fluorinated on urea moiety and differently decorated on pyrazo

AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.